Inhaled Zanamivir vs Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study.

Chia-Ping SuK Arnold ChanChing Tai HuangChi-Tai Fang

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Inhaled zanamivir is not inferior to oral oseltamivir as outpatient treatment in preventing influenza-related hospitalization or death for patients whose conditions do not require hospitalization within 2 days.

Keyphrases

end stage renal disease
cystic fibrosis
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
solid state